Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Autolus Therapeutics ( (AUTL) ) has provided an update.
On January 21, 2026, Autolus Limited, a subsidiary of Autolus Therapeutics, entered into a new ten-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vectors, replacing a prior arrangement between the parties. The non-exclusive agreement sets out general commercial and regulatory terms and commits Autolus to purchase a minimum of 14 batches of lentiviral vector in the first two calendar years and at least EUR 25 million of products and services over the following five-year period, while giving AGC a first right to negotiate for new manufacturing activities related to Autolus’s obe-cel product, thereby securing a key component of Autolus’s CAR-T manufacturing supply chain and reinforcing long-term operational planning for its lead therapy.
The most recent analyst rating on (AUTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses, negative gross profit, and substantial cash burn—despite strong revenue growth. Technicals add downside risk with the stock trading below major moving averages and weak momentum. Offsetting factors include constructive earnings-call updates on launch execution, access, and manufacturing performance, but near-term margins and operating losses remain a key constraint.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics plc is a biotechnology company focused on developing and manufacturing CAR-T cell therapies, with its operations relying on lentiviral vectors as a critical raw material for both clinical and commercial production of these products.
Average Trading Volume: 3,004,152
Technical Sentiment Signal: Sell
Current Market Cap: $388.6M
For detailed information about AUTL stock, go to TipRanks’ Stock Analysis page.